ArticleAntimicrobial resistance and infection control2026
A machine learning-driven multitask framework for antibiotic resistance prediction in Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae bloodstream infections among hematological malignancy patients.
Article in Antimicrobial resistance and infection control, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundInappropriate empirical antimicrobial therapy (IEAT) significantly increases mortality in patients with resistant Gram-negative bacteremia. We developed a multitask machine learning framework to predict carbapenem resistance (CR), β-lactam/β-lactamase inhibitor combinations resistance (BL/BLI-R), and third-/fourth-generation cephalosporins resistance (3GC/4GC-R) in HM patients with monomicrobial BSIs caused specifically by Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae.
methodsUsing retrospective data from 1,353 HM patients with three specific Enterobacterales BSIs (2017-2023), we trained support vector machines, eXtreme Gradient Boosting, and logistic regression models through 5-fold cross-validation with hyperparameter tuning and conducting internal validation via bootstrap. Model thresholds were optimized via Pareto front analysis to minimized IEAT and carbapenem use while maximizing sensitivity.
resultsThe models achieved AUCs of 0.81 (95% CI, 0.78-0.85) for CR model, 0.81 (95% CI, 0.77-0.84) for BL/BLI-R model, and 0.72 (95% CI, 0.68-0.76) for 3GC/4GC-R model before optimization. Threshold optimization improved sensitivity for CR prediction increased from 0.10 to 0.77, for BL/BLI-R prediction from 0.19 to 0.94, and for 3GC/4GC-R prediction from 0.54 to 0.98. SHAP analysis identified key predictors including prolonged neutropenia, prior carbapenem exposure, and tumor consolidation stage. Integrating pathogen species enhanced 3GC/4GC-R prediction (AUC 0.72 vs. 0.76). Clinically, by employing the threshold optimization strategy, the model successfully reduced empirical carbapenem use from 71.7% to 32.1% without increasing the rate of IEAT compared to clinical practice (4.0% vs. 6.11%).
conclusionThis multitask framework supports resistance prediction in HM patients with monomicrobial BSIs due to three specific Enterobacterales species, mainly used to assist clinical decision-making after pathogen identification and strongly suspected infection with one of the three pathogens. Prospective validation is required before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.